Search

Introduction: This study aimed to investigate the oncological outcomes and toxicity profile of 177 Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC)., Patients and Methods: A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177 Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1-7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria., Results: In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177 Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%-99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC., Conclusions: 177 Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177 Lu-PSMA-I&T RLT in the management of metastatic prostate cancer., Competing Interests: Conflicts of interest and sources of funding: B.E. is supported by the European Urological Scholarship Programme through a 1-year research scholarship., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Intraglomerular metastasis is a very rare condition with an underlying cause that is not yet well understood. We present the 18F-FDG PET/CT images of histologically proven intraglomerular metastases from newly diagnosed malignant melanoma with positive sentinel lymph node metastases. During the initial diagnostic evaluation period, the patient also had a sudden increased serum creatinine level. FDG PET/CT demonstrated diffuse glomerular FDG uptake unlike typical physiologic pelvicaliceal activity. Renal biopsy revealed diffuse crescentic lesions containing metastatic melanoma cells.